Learn about overcoming regulatory challenges, establishing intellectual property, and developing novel psychedelic drug treatment options for chronic pain in this webinar hosted by Jim Gilligan, co-founder and Managing Partner of Bracken, as well as President and Chief Scientific Officer of Tryp Therapeutics.
Jim has a deep history of drug development and strategic planning, pharmacology and toxicology, due diligence, peptide-based therapeutics, rDNA product development, musculoskeletal diseases, cardiovascular disease, and psychedelic assisted psychotherapy. Jim has co-founded and helped lead multiple biopharma and bio-tech companies, including Tryp Therapeutics, Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. He has executed numerous feasibility and licensing deals within the pharmaceutical industry, working frequently with investment bankers, venture capitalists, and brokers.
